Sales of products with expired patents (Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra) decreased by a combined CHF 0.4 billion at CER, or CHF 0.6 billion in CHF. (Roche Press Release) Oct 22, 2026
Sales • Burkitt Lymphoma • Cervical Cancer • Chronic Lymphocytic Leukemia • Diabetic Macular Edema • Diabetic Retinopathy • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastroesophageal Junction Adenocarcinoma • Giant Cell Arteritis • Glioblastoma • Hepatocellular Cancer • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Lung Non-Squamous Non-Small Cell Cancer • Macular Degeneration • Marginal Zone Lymphoma • Neurofibromatosis • Ovarian Cancer • Rheumatoid Arthritis • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • Wet Age-related Macular Degeneration
|